CRNX

SEC source: 0001209191-22-015131 · doc4.xml · nonDerivative · entry 2

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,995

F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-015130 · doc4.xml · derivative · entry 3

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2032-02-27

F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015130 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,083

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.

SEC source: 0001209191-22-015131 · doc4.xml · derivative · entry 3

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,400

Underlying: Common Stock · 65,400 shares

Expires 2032-02-27

F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015131 · doc4.xml · nonDerivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,995

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.

SEC source: 0001209191-22-015134 · doc4.xml · derivative · entry 7

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,200

Underlying: Common Stock · 249,200 shares

Expires 2032-02-27

F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015134 · doc4.xml · nonDerivative · entry 1

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,400

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023..

SEC source: 0001209191-22-015133 · doc4.xml · derivative · entry 2

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,100

Underlying: Common Stock · 23,100 shares

Expires 2032-02-27

F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015133 · doc4.xml · nonDerivative · entry 1

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,950

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.

SEC source: 0001209191-22-015132 · doc4.xml · derivative · entry 2

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2032-02-27

F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015132 · doc4.xml · nonDerivative · entry 1

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,618

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023..

SEC source: 0001209191-22-015129 · doc4.xml · derivative · entry 2

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,500

Underlying: Common Stock · 66,500 shares

Expires 2032-02-27

F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022.

SEC source: 0001209191-22-015129 · doc4.xml · nonDerivative · entry 1

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,561

F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.

SEC source: 0001209191-22-010784 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,583

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-008061 · doc4.xml · nonDerivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,045

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $17.170 and $18.015. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001209191-22-006797 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,706

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · balance_after: Includes 954 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2021 by the Reporting Person.

SEC source: 0001209191-22-004453 · doc4.xml · derivative · entry 3

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,473

Underlying: Common stock · 6,700 shares

Expires 2028-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F4 · derivative.exercise_date: Stock option granted June 16, 2018 with 25% vesting on the first anniversary of the grant date and the remainder vesting in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-22-004453 · doc4.xml · nonDerivative · entry 2

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,311

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $20.77 and $21.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001209191-22-004453 · doc4.xml · nonDerivative · entry 1

Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,011

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · balance_after: Includes 1,928 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.

SEC source: 0001209191-22-004051 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,875

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-002197 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,043

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-002705 · doc4.xml · derivative · entry 1

Vivaldi Coelho Rogerio · CIK 0001610381 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-12-31

F1 · derivative.exercise_date: The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date.

SEC source: 0001209191-22-022681 · doc4a.xml · derivative · entry 1

Vivaldi Coelho Rogerio · CIK 0001610381 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-12-31

F1 · shares: On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

F2 · derivative.exercise_date: The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the date of grant, subject to continued service as a director through each such vesting date.

F1 · derivative.underlying_shares: On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

F1 · balance_after: On January 10, 2022, the reporting person filed a Form 4 which inadvertently reported that he was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.

SEC source: 0001209191-21-071646 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,211

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.9506 per share. The range of sales prices on the transaction date was $27.950 to $27.952 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-21-070272 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,211

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-067840 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,879

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-22-007198 · doc5.xml · nonDerivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,456

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

SEC source: 0001209191-22-007202 · doc5.xml · nonDerivative · entry 2

Wilson Marc · CIK 0001702265 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,118

F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

SEC source: 0001209191-21-065149 · doc4.xml · nonDerivative · entry 2

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,547

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-065149 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,047

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-063679 · doc4.xml · nonDerivative · entry 2

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,715

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $28.422 per share. The range of sales prices on the transaction date was $28.340 to $28.500 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-21-063679 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,615

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.952 per share. The range of sales prices on the transaction date was $27.950 to $27.959 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0001209191-21-062731 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,215

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-062728 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,092

Underlying: Common stock · 8,954 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-062728 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-062728 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,490

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-062263 · doc4.xml · derivative · entry 2

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 106,383 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares subject to the option vested on July 17, 2017 and 1/48th of the total remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-21-062263 · doc4.xml · nonDerivative · entry 1

Madan Ajay · CIK 0001807856 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,671

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 772 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.

SEC source: 0001209191-21-061915 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,883

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.997 per share. The range of sales prices on the transaction date was $23.970 to $24.003 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

SEC source: 0000899243-21-041399 · doc4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,163,517

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-21-061496 · doc4.xml · nonDerivative · entry 1

Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,883

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-055314 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,046

Underlying: Common stock · 6,046 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-055314 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-055314 · doc4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 6

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 4

Disclosed balance after: 90,000

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 5

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 3

Disclosed balance after: 90,000

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 4

Struthers Richard Scott · CIK 0001746298 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust 2

Disclosed balance after: 90,000

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

SEC source: 0001209191-21-054490 · doc4.xml · derivative · entry 1

Knight Jeff E. · CIK 0001881007 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2031-08-30

F1 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

SEC source: 0001209191-21-048375 · doc4.xml · derivative · entry 3

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,092

Underlying: Common stock · 5,000 shares

Expires 2028-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

SEC source: 0001209191-21-048375 · doc4.xml · nonDerivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,536

F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.